Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASCO GI 2022

20 - 22 Jan 2022

Moscone West, San Francisco, United States of America

Tumour agnostic treatments in GI cancer

Dr Nicola Normanno and Dr Katja Schmitz

Tumour agnostic treatments in GI cancer ( Dr Nicola Normanno and Dr Katja Schmitz )

Durvalumab plus chemotherapy significantly improved OS in advanced biliary...

Dr Do-Youn Oh - Seoul National University College of Medicine, Seoul, South...

Durvalumab plus chemotherapy significantly improved OS in advanced biliary tract cancer ( Dr Do-Youn Oh - Seoul National University College of Medicine, Seoul, South Korea )

Early treatment discontinuation and early oxaliplatin discontinuation for stage...

Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France

Early treatment discontinuation and early oxaliplatin discontinuation for stage III colorectal cancer ( Dr Claire Gallois - Hôpitaux Universitaires Paris-Ouest, Paris, France )

HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in...

Dr Ghassan K. Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA

HIMALAYA: Study of tremelimumab and durvalumab as first-line therapy in patients with uHCC ( Dr Ghassan K. Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York, USA )

Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant...

Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan

Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced oesophageal cancer ( Dr Ken Kato - National Cancer Center Hospital, Tokyo, Japan )

Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan

Nivo + chemo vs chemo as first-line treatment for advanced GC/GEJC/EAC ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )

More from ecancer